Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 22 Publications

5 Customer Reviews

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

  • Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 M4PLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\RUW1KSzVyPUCuNFAxOjh5IN88US=> M4TnOXNCVkeHUh?=
LC-2-ad NXfvUJBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMECwN|E4KM7:TR?= MYHTRW5ITVJ?
RL95-2 M2jVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMECwOlY5KM7:TR?= MXTTRW5ITVJ?
MZ1-PC NX3XWIp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjaR3FKSzVyPUCuNFAxPzJ7IN88US=> NEnwSIZUSU6JRWK=
TE-8 M4PIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHXSo1KSzVyPUCuNFAyOTdizszN MXzTRW5ITVJ?
SW954 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMECxNVkh|ryP M{H0Z3NCVkeHUh?=
TE-11 MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnHO|FKSzVyPUCuNFAyOjNizszN NEjnbVBUSU6JRWK=
PSN1 NID6SHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMECxN{DPxE1? MX\TRW5ITVJ?
MOLT-4 NV;CSm1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\v[IlKSzVyPUCuNFAyPDlizszN NHrJW3dUSU6JRWK=
697 NWH2bXdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M334[mlEPTB;MD6wNFE2KM7:TR?= M1XGfHNCVkeHUh?=
ETK-1 M4nzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\2TWM2OD1yLkCwNVUzKM7:TR?= MUDTRW5ITVJ?
TE-10 M3vVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnQTWM2OD1yLkCwNVU1KM7:TR?= NGrpWGFUSU6JRWK=
HUTU-80 NHexcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMECxOlgh|ryP MUXTRW5ITVJ?
NTERA-S-cl-D1 NI\XUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXhTWM2OD1yLkCwNlA6KM7:TR?= Ml\4V2FPT0WU
MFH-ino MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\NR45kUUN3ME2wMlAxOjZ6IN88US=> MYrTRW5ITVJ?
IA-LM NIHhNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMECyPEDPxE1? MlTaV2FPT0WU
MC116 MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMECyPFkh|ryP NXHsS2dmW0GQR1XS
RKO M2nwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\rbWlEPTB;MD6wNFI6QCEQvF2= NUe4PG9sW0GQR1XS
MRK-nu-1 M4PNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrTendKSzVyPUCuNFAzQTlizszN MWDTRW5ITVJ?
VA-ES-BJ MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4KzPWlEPTB;MD6wNFMh|ryP MYPTRW5ITVJ?
KALS-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;USXNKSzVyPUCuNFA{ODhizszN NFTKTZdUSU6JRWK=
BB30-HNC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke0TWM2OD1yLkCwN|E1KM7:TR?= NVfMdYVOW0GQR1XS
ACN MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jjOGlEPTB;MD6wNFMyPiEQvF2= M{DTc3NCVkeHUh?=
TE-9 Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVmyVlJQUUN3ME2wMlAxOzJ4IN88US=> M4LlOnNCVkeHUh?=
SIG-M5 M1\VWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\zTWM2OD1yLkCwN|I4KM7:TR?= MkDiV2FPT0WU
no-10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV32UYFRUUN3ME2wMlAxOzZ{IN88US=> MYfTRW5ITVJ?
EW-1 NWjJ[Jh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnG[Y5OUUN3ME2wMlAxOzdzIN88US=> M{PqWnNCVkeHUh?=
SK-LMS-1 Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTBVplqUUN3ME2wMlAxPDBzIN88US=> Ml73V2FPT0WU
GT3TKB MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXHVmVKSzVyPUCuNFA1OzRizszN MX;TRW5ITVJ?
ES4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLUTWM2OD1yLkCwOFQ6KM7:TR?= M2LwSnNCVkeHUh?=
IMR-5 M{XUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHnNWV{UUN3ME2wMlAxPDVizszN NIm4d4hUSU6JRWK=
NCI-H1648 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwMEC0Olkh|ryP NFLadHlUSU6JRWK=
MV-4-11 Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMEC0O|Uh|ryP MoGzV2FPT0WU
SK-UT-1 NHvVfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMEC0PEDPxE1? Mo\lV2FPT0WU
NB13 M1\Y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlqzTWM2OD1yLkCwOFkyKM7:TR?= MnrBV2FPT0WU
DJM-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMEC1N{DPxE1? MWDTRW5ITVJ?
ES8 NFXJR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjYTWM2OD1yLkCwOVM5KM7:TR?= MUnTRW5ITVJ?
TE-6 MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzrZZc2UUN3ME2wMlAxPTdizszN M{XuTXNCVkeHUh?=
KS-1 M1\zXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn2U5IxUUN3ME2wMlAxPTh{IN88US=> NGDCPItUSU6JRWK=
TE-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn31TWM2OD1yLkCwOlA3KM7:TR?= NUPGVWpOW0GQR1XS
ATN-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TjS2lEPTB;MD6wNFYxQSEQvF2= NH[weGlUSU6JRWK=
A4-Fuk NWPDTmVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXF[oRUUUN3ME2wMlAxPjFzIN88US=> MXTTRW5ITVJ?
ALL-PO MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvJfmNuUUN3ME2wMlAxPjNizszN MYfTRW5ITVJ?
BE-13 NIDBZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly4TWM2OD1yLkCwOlM3KM7:TR?= MXPTRW5ITVJ?
KM12 M3HVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTIfJVDUUN3ME2wMlAxPjN5IN88US=> MVTTRW5ITVJ?
NOS-1 MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjqS|E{UUN3ME2wMlAxPjVizszN M3nqOHNCVkeHUh?=
SW962 M33mPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMEC2OlIh|ryP NYmyW2JmW0GQR1XS
OCUB-M M1viVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPmSJlKSzVyPUCuNFA3PjJizszN MV;TRW5ITVJ?
NCI-H510A NYDndYdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYSze4l1UUN3ME2wMlAxPjZ3IN88US=> M1;VPXNCVkeHUh?=
EW-16 NXnyZWJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzXTWM2OD1yLkCwOlk1KM7:TR?= NWPyeodiW0GQR1XS
KGN M4DV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnaTWM2OD1yLkCwO|EzKM7:TR?= NV7l[JZIW0GQR1XS
LS-411N NW\CbIVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfjVVg4UUN3ME2wMlAxPzF5IN88US=> MWnTRW5ITVJ?
Becker M3nGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rpTGlEPTB;MD6wNFczKM7:TR?= M4fTW3NCVkeHUh?=
HC-1 NELuWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDM[2tOUUN3ME2wMlAxPzJzIN88US=> MoXIV2FPT0WU
CESS NX\FS21FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnMXIJKSzVyPUCuNFA4OzdizszN MYTTRW5ITVJ?
KURAMOCHI MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLRc5BkUUN3ME2wMlAxPzR6IN88US=> NID0e2VUSU6JRWK=
TGBC24TKB Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEC3OVIh|ryP MmCzV2FPT0WU
SW982 NFP0ZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPyTWM2OD1yLkCwO|Y3KM7:TR?= MnTEV2FPT0WU
HCE-4 NUDWbZM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPBOI1KSzVyPUCuNFA4PjdizszN NVnKdZcxW0GQR1XS
LOUCY NXj0TpB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\xSI12UUN3ME2wMlAxPzd3IN88US=> MWHTRW5ITVJ?
8-MG-BA NGDjeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPYUolKSzVyPUCuNFA4QTZizszN MWDTRW5ITVJ?
HT-144 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMEC4JO69VQ>? NYTmVXZFW0GQR1XS
LXF-289 MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XF[GlEPTB;MD6wNFgyQCEQvF2= NXvNUFhFW0GQR1XS
RS4-11 MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;0NIRMUUN3ME2wMlAxQDN4IN88US=> NH\SVllUSU6JRWK=
DEL M13n[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEC4OFUh|ryP M3H3[HNCVkeHUh?=
OCI-AML2 M1e3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfmTWM2OD1yLkCwPFUzKM7:TR?= NYnsdYFJW0GQR1XS
CCRF-CEM NX;2emtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXCXndJUUN3ME2wMlAxQDdzIN88US=> NF\rZ3NUSU6JRWK=
A388 M13GZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP3TWM2OD1yLkCwPFc1KM7:TR?= MnLQV2FPT0WU
KNS-42 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrEdotUUUN3ME2wMlAxQDlzIN88US=> NHG0S29USU6JRWK=
OVCAR-4 NULXSpNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HQVmlEPTB;MD6wNFkxPCEQvF2= M{XaR3NCVkeHUh?=
NCI-H1355 NF7hdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XXXGlEPTB;MD6wNFkyPCEQvF2= M3XwN3NCVkeHUh?=
BL-70 M3TZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMEC5N{DPxE1? NV;lb2luW0GQR1XS
BL-41 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;IdXBwUUN3ME2wMlAxQTN2IN88US=> Mk\3V2FPT0WU
A101D MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHnZXJQUUN3ME2wMlAxQTZizszN NVK0XGhJW0GQR1XS
HL-60 NV3G[HNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XxemlEPTB;MD6wNFk3PiEQvF2= MkX6V2FPT0WU
COR-L279 MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHToWJRKSzVyPUCuNFA6QTlizszN MoDXV2FPT0WU
NCI-SNU-16 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C4fmlEPTB;MD6wNVAxQCEQvF2= NVfQ[|AyW0GQR1XS
Calu-6 M{\YPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLHU29tUUN3ME2wMlAyODF{IN88US=> MmXhV2FPT0WU
SR NET2PYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTBZ5NKSzVyPUCuNFExOjZizszN MWnTRW5ITVJ?
QIMR-WIL MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWryVIloUUN3ME2wMlAyODN|IN88US=> MWHTRW5ITVJ?
LB647-SCLC MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[5U|VKSzVyPUCuNFExPTFizszN M1m3[nNCVkeHUh?=
RPMI-8226 M4[1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3lOphKSzVyPUCuNFEyODJizszN NEXxSodUSU6JRWK=
SK-PN-DW NYTVbIVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonITWM2OD1yLkCxNVEzKM7:TR?= M2H5RXNCVkeHUh?=
SF268 MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDKcYhnUUN3ME2wMlAyOTVzIN88US=> NXO1Z4pnW0GQR1XS
HD-MY-Z MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTjcHBKSzVyPUCuNFEyPjNizszN MXjTRW5ITVJ?
DOHH-2 M3XZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXBWGxKSzVyPUCuNFEzODNizszN MlvOV2FPT0WU
SCC-3 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTUbYlKSzVyPUCuNFEzODRizszN NIXDZ4lUSU6JRWK=
ST486 M1K5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fwSGlEPTB;MD6wNVIxPCEQvF2= M{LEcnNCVkeHUh?=
NALM-6 M2n2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\6R2lEPTB;MD6wNVIyPCEQvF2= NIPkUppUSU6JRWK=
NCI-H1436 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMEGyN|Eh|ryP NUTvZ|JnW0GQR1XS
KE-37 M{jWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC5TWM2OD1yLkCxNlM1KM7:TR?= M3TIWnNCVkeHUh?=
RPMI-8402 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e5dmlEPTB;MD6wNVI2PiEQvF2= MWfTRW5ITVJ?
RXF393 NVLiWYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEGyOVch|ryP MnnwV2FPT0WU
KARPAS-45 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7Kb45yUUN3ME2wMlAyOjdizszN MVXTRW5ITVJ?
HOP-62 NHrWWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXkfVNKSzVyPUCuNFEzPzZizszN NXjBXGdmW0GQR1XS
ES1 M{HFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTzTWM2OD1yLkCxNlg5KM7:TR?= MUHTRW5ITVJ?
L-363 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17qNWlEPTB;MD6wNVM2OSEQvF2= NWjaWIZwW0GQR1XS
GI-1 M{DDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnUTWM2OD1yLkCxN|c{KM7:TR?= MVzTRW5ITVJ?
CTV-1 MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEG0O|gh|ryP NXrPXGx1W0GQR1XS
TE-5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;0d4FKSzVyPUCuNFE1QTZizszN Ml3QV2FPT0WU
SNU-C2B NVH6b4FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHDcm1KSzVyPUCuNFE1QTZizszN NYrlW4dUW0GQR1XS
K-562 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7lTWM2OD1yLkCxOVE3KM7:TR?= NIfaUXBUSU6JRWK=
SNB75 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\S[5dKSzVyPUCuNFE2PCEQvF2= M1;TO3NCVkeHUh?=
MOLT-13 Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nMPWlEPTB;MD6wNVY{PyEQvF2= MmnZV2FPT0WU
LS-123 NGGzNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvQPXNiUUN3ME2wMlAyPjZ2IN88US=> M4fhcnNCVkeHUh?=
NCI-SNU-5 MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Prd2lEPTB;MD6wNVcxOSEQvF2= NV:3cJhbW0GQR1XS
Daudi NYP0[|JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYez[JhIUUN3ME2wMlAyPzB6IN88US=> NUX6e4hsW0GQR1XS
A253 NX\jd3JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37QWGlEPTB;MD6wNVc{QCEQvF2= NWjLelF1W0GQR1XS
TGBC1TKB NUS5dllKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\IU2lEPTB;MD6wNVc2OiEQvF2= M4K5VHNCVkeHUh?=
SJSA-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\6TWM2OD1yLkCxO|Y4KM7:TR?= Mo[1V2FPT0WU
NCCIT M1X5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnFTWM2OD1yLkCxO|Y6KM7:TR?= MonCV2FPT0WU
NCI-H69 NFXFfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnYdpNuUUN3ME2wMlAyPzd6IN88US=> NWDjWFJEW0GQR1XS
SH-4 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C1WWlEPTB;MD6wNVg6PSEQvF2= NFPaSnpUSU6JRWK=
HCC1187 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMEG5NlQh|ryP NXuxXYtWW0GQR1XS
HCC1599 NUjIV3JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvpTWM2OD1yLkCyNFIh|ryP NWXDd4pKW0GQR1XS
ONS-76 M3nBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;6T4JKSzVyPUCuNFIxOzZizszN MmntV2FPT0WU
KU812 NXjubphkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIToNYhKSzVyPUCuNFIxOzlizszN M{PyVHNCVkeHUh?=
ML-2 M4G3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMEKwOFch|ryP MoXxV2FPT0WU
HCE-T NWno[5d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS2TWM2OD1yLkCyNFkzKM7:TR?= NELEPZpUSU6JRWK=
NCI-H446 NFG5flJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\SPI1KSzVyPUCuNFIyOTJizszN M4Pzc3NCVkeHUh?=
RPMI-6666 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHxSJdKSzVyPUCuNFIyPDlizszN MXjTRW5ITVJ?
MOLT-16 M1r0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3STWM2OD1yLkCyNVU{KM7:TR?= M{P3[HNCVkeHUh?=
JiyoyeP-2003 NXrFNZA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXZUnZKSzVyPUCuNFIyPzZizszN MXvTRW5ITVJ?
MHH-PREB-1 Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;iTWM2OD1yLkCyNVkyKM7:TR?= NFH1dlhUSU6JRWK=
MC-CAR M2jvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fUXWlEPTB;MD6wNlMzPiEQvF2= MmHQV2FPT0WU
BC-3 NFXtXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPDfotKSzVyPUCuNFI{PDRizszN MYTTRW5ITVJ?
KINGS-1 MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMEKzOVUh|ryP MXfTRW5ITVJ?
PF-382 NInu[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\qV2lEPTB;MD6wNlM4QCEQvF2= NFPKelVUSU6JRWK=
J-RT3-T3-5 NH\YUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMEKzPFMh|ryP NGWyZ3VUSU6JRWK=
SF539 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXKPHZWUUN3ME2wMlAzPDBzIN88US=> MVnTRW5ITVJ?
LB831-BLC MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:1eXM5UUN3ME2wMlAzPDh3IN88US=> MoPZV2FPT0WU
DMS-114 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEK1NFIh|ryP MXvTRW5ITVJ?
LB1047-RCC MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILDRXlKSzVyPUCuNFI2OSEQvF2= MXLTRW5ITVJ?
LB771-HNC NVXXU4FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPBNGFKSzVyPUCuNFI2OzRizszN MnfEV2FPT0WU
BB65-RCC NGnISodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f6ZmlEPTB;MD6wNlU{PCEQvF2= NWXNcmVVW0GQR1XS
BV-173 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMEK1OVQh|ryP NYXpN5BKW0GQR1XS
ARH-77 NWLhZXNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O1PGlEPTB;MD6wNlYxOSEQvF2= NV\O[lRzW0GQR1XS
IST-MEL1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljOTWM2OD1yLkCyOlI{KM7:TR?= NF3CUXdUSU6JRWK=
NB1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnNe|NHUUN3ME2wMlAzPjh5IN88US=> MojTV2FPT0WU
EoL-1-cell NVzt[FFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLPTWM2OD1yLkCyOlg5KM7:TR?= NHrRbZpUSU6JRWK=
KY821 NX\SWlZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3oW3hKSzVyPUCuNFI3QTdizszN MUnTRW5ITVJ?
CMK MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMEK3N|Qh|ryP NYTR[pBoW0GQR1XS
NCI-H2126 NXrQSms3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTjOJBTUUN3ME2wMlAzPzZ6IN88US=> NVXaPWI3W0GQR1XS
NCI-H526 NH;Zd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn2TWM2OD1yLkCyPFkyKM7:TR?= NYHsWYdQW0GQR1XS
COLO-684 NWT3VnhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEK5NFgh|ryP M2S4[HNCVkeHUh?=
NCI-H747 M2ryV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fCOmlEPTB;MD6wNlk{OyEQvF2= NUHON3VTW0GQR1XS
JAR NGPYbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDZTWM2OD1yLkCyPVQ3KM7:TR?= NIfJZW1USU6JRWK=
MEG-01 NIrYVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHISFFKSzVyPUCuNFI6PzhizszN M1nEPXNCVkeHUh?=
MONO-MAC-6 NXLtN5dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLxTWM2OD1yLkCzNFI{KM7:TR?= MW\TRW5ITVJ?
IST-SL1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm5TWM2OD1yLkCzNFQzKM7:TR?= MlrMV2FPT0WU
CPC-N NWfPUplOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPPbVFKSzVyPUCuNFMxPzlizszN MY\TRW5ITVJ?
NCI-H1963 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjlRm1{UUN3ME2wMlA{OTNzIN88US=> NV\2dGsyW0GQR1XS
K052 NEexN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL4TJU6UUN3ME2wMlA{OjR5IN88US=> MmGwV2FPT0WU
KM-H2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHPTWM2OD1yLkCzN|A4KM7:TR?= MYPTRW5ITVJ?
TE-12 M4\Sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL2O2FKSzVyPUCuNFM{ODlizszN M4TC[nNCVkeHUh?=
TK10 M2DITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMEOzOVYh|ryP M3Hnd3NCVkeHUh?=
NMC-G1 NWDjO2k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\xTWM2OD1yLkCzOFUzKM7:TR?= M1zLOXNCVkeHUh?=
no-11 MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEO0O|gh|ryP NFrF[oRUSU6JRWK=
NCI-H524 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPnTWM2OD1yLkCzOVI6KM7:TR?= M1qzW3NCVkeHUh?=
MHH-CALL-2 NGizZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLEeHlKSzVyPUCuNFM2PjJizszN MnPQV2FPT0WU
GB-1 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID2c4pKSzVyPUCuNFM3KM7:TR?= NXXkOo9oW0GQR1XS
OPM-2 NILveZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\kTWM2OD1yLkCzOlc{KM7:TR?= NXPFZ3hbW0GQR1XS
RH-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj3TWM2OD1yLkCzPFE6KM7:TR?= NH3EOnVUSU6JRWK=
NCI-H64 NGHwUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjaVYdKSzVyPUCuNFM5PTdizszN MnzoV2FPT0WU
EVSA-T MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\6SphKSzVyPUCuNFM6OjNizszN NX3qSHBvW0GQR1XS
KARPAS-299 MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z3U2lEPTB;MD6wN|k5KM7:TR?= NVLRSlZ7W0GQR1XS
MZ7-mel M17icGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnThTWM2OD1yLkC0NFQh|ryP NUKwRnl4W0GQR1XS
LB373-MEL-D M{HUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv0TWM2OD1yLkC0NVA2KM7:TR?= NGPhOJBUSU6JRWK=
HEL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDSdWRKSzVyPUCuNFQyPCEQvF2= M163W3NCVkeHUh?=
SW872 NV3HSJl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzPWXhKSzVyPUCuNFQzOSEQvF2= NFLGZm1USU6JRWK=
DU-4475 M4j2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7xTWM2OD1yLkC0NlQ1KM7:TR?= M1LxbHNCVkeHUh?=
IST-SL2 NEPtdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrkTWM2OD1yLkC0Nlc2KM7:TR?= MX3TRW5ITVJ?
NCI-H82 M1:wZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMESzNFch|ryP NInkUHZUSU6JRWK=
LC4-1 M{DwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW5NWNqUUN3ME2wMlA1OzVzIN88US=> M2PpRXNCVkeHUh?=
HDLM-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\SWW01UUN3ME2wMlA1Ozl{IN88US=> NYTsV|BwW0GQR1XS
MMAC-SF MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rtemlEPTB;MD6wOFU{PCEQvF2= NUS0S2lXW0GQR1XS
L-540 NYm1[lJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPGOHJTUUN3ME2wMlA1PjN7IN88US=> MVzTRW5ITVJ?
MZ2-MEL NFXHZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHyb4NKSzVyPUCuNFQ4PDJizszN MVTTRW5ITVJ?
LU-134-A NV:0fGpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HPPGlEPTB;MD6wOFc4OyEQvF2= M{DySnNCVkeHUh?=
UACC-257 Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnNXndKSzVyPUCuNFQ5PDlizszN M2rVU3NCVkeHUh?=
NCI-H1581 MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMES5OVMh|ryP NH;5NppUSU6JRWK=
NB17 NHjTNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnzdmZ5UUN3ME2wMlA1QTd7IN88US=> Mn\aV2FPT0WU
SBC-1 NWHGZYtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELUW4NKSzVyPUCuNFUxPDJizszN MVvTRW5ITVJ?
TALL-1 M{TPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljDTWM2OD1yLkC1NFQ2KM7:TR?= MXHTRW5ITVJ?
NCI-H1304 M2rDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP4TWM2OD1yLkC1NlA5KM7:TR?= NVTrSpNuW0GQR1XS
NEC8 M4noPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jSWmlEPTB;MD6wOVI5PiEQvF2= NGD6em9USU6JRWK=
CAL-148 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\STWM2OD1yLkC1OFM6KM7:TR?= MVPTRW5ITVJ?
CGTH-W-1 NFfBTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[4WmlEPTB;MD6wOVQ1QSEQvF2= MVLTRW5ITVJ?
NCI-H889 NI\RSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKxbHRKSzVyPUCuNFU2QTJizszN M2X3XnNCVkeHUh?=
GR-ST NEDUVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj5TWM2OD1yLkC1OlIyKM7:TR?= NXrPS3ZFW0GQR1XS
KARPAS-422 MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPXUVg6UUN3ME2wMlA2PjVizszN MlPpV2FPT0WU
RPMI-8866 NIfHUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjWTWM2OD1yLkC1O|EzKM7:TR?= MXzTRW5ITVJ?
SCLC-21H NIrRW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G5fGlEPTB;MD6wOVg5PCEQvF2= NEHMVZdUSU6JRWK=
COR-L88 M3P1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjH[|dPUUN3ME2wMlA2QTJ5IN88US=> NHjtW3BUSU6JRWK=
LU-139 NEX0SZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMEW5PFYh|ryP M3HneHNCVkeHUh?=
SF126 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3ZTWM2OD1yLkC2NVM{KM7:TR?= NGnCPYxUSU6JRWK=
NCI-H1882 MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjmWmlKUUN3ME2wMlA3PDJ2IN88US=> NGPlUGxUSU6JRWK=
EW-24 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nlTGlEPTB;MD6wOlQ5OyEQvF2= MlfZV2FPT0WU
CP67-MEL NUfv[3QyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwME[4NUDPxE1? MUjTRW5ITVJ?
DG-75 MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT2S5ZKSzVyPUCuNFY5QTlizszN MmKwV2FPT0WU
LOXIMVI NY\ZSmFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13OVWlEPTB;MD6wO|AzQCEQvF2= MmTlV2FPT0WU
HH MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnQeWd4UUN3ME2wMlA4OTV5IN88US=> MWrTRW5ITVJ?
K5 NHrHbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELveINKSzVyPUCuNFczOjZizszN NEKzdolUSU6JRWK=
EC-GI-10 NWL1Vm9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMEeyOVch|ryP MXnTRW5ITVJ?
SK-N-DZ MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fLS2lEPTB;MD6wO|MxPyEQvF2= NHHLfJJUSU6JRWK=
A3-KAW NInIcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrJO|JKSzVyPUCuNFc{PTFizszN Mk[3V2FPT0WU
MLMA MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rF[2lEPTB;MD6wO|Q3PSEQvF2= NHG2TWxUSU6JRWK=
LB996-RCC NIC0PVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G2fmlEPTB;MD6wO|cxPyEQvF2= NELjZmRUSU6JRWK=
OS-RC-2 M1zRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknqTWM2OD1yLkC3O|Q5KM7:TR?= MnT1V2FPT0WU
CTB-1 M{T4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjmTWM2OD1yLkC3PFEh|ryP MlvVV2FPT0WU
IST-MES1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TNW2lEPTB;MD6wO|kyOiEQvF2= MWTTRW5ITVJ?
LS-1034 NEC4O3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfFTWM2OD1yLkC4NFM2KM7:TR?= NHzTSYxUSU6JRWK=
HT MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfifG9KSzVyPUCuNFgxQDZizszN M1jsenNCVkeHUh?=
NCI-H2141 MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7VSldJUUN3ME2wMlA5OSEQvF2= MYDTRW5ITVJ?
LB2518-MEL NVP0NnpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3vbYw6UUN3ME2wMlA5OTRzIN88US=> NHjJeVFUSU6JRWK=
GI-ME-N M4fiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMEi0OVIh|ryP MV;TRW5ITVJ?
TGW MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEi2NFch|ryP MlLtV2FPT0WU
SK-NEP-1 NEiwVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoiwTWM2OD1yLkC4OlQyKM7:TR?= MlG5V2FPT0WU
NOMO-1 M2HzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;JTWM2OD1yLkC5Nlc2KM7:TR?= NYn5SIc{W0GQR1XS
ES6 NX7aRok6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnxb|BKSzVyPUCuNFk2QDlizszN M37MNXNCVkeHUh?=
NCI-H209 M4DYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEm3PFYh|ryP M2S1SXNCVkeHUh?=
GAK M2\nVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfWfYpKSzVyPUCuNVAyPiEQvF2= NVTIRXlYW0GQR1XS
BC-1 NIn0WYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW0VpA2UUN3ME2wMlExOzZzIN88US=> NVq3UI5SW0GQR1XS
KLE NILSTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rFfGlEPTB;MD6xNFQ1OyEQvF2= M12yVXNCVkeHUh?=
EW-3 NUjvWJdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H3Z2lEPTB;MD6xNFk5KM7:TR?= NHLMeHJUSU6JRWK=
NKM-1 MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXWxd2lLUUN3ME2wMlEyOSEQvF2= MlvhV2FPT0WU
D-336MG MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjZTWM2OD1yLkGxNlQ1KM7:TR?= NIHwOopUSU6JRWK=
NB69 NV7CS|VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMUGzNFEh|ryP M1HWcnNCVkeHUh?=
D-263MG MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMUG3NVIh|ryP M1;sSHNCVkeHUh?=
KP-N-YS M3X5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjjTWM2OD1yLkGyNlkyKM7:TR?= MXLTRW5ITVJ?
NCI-H1155 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMUK1OVgh|ryP Mk\aV2FPT0WU
BOKU NYfwcGJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXTdYRJUUN3ME2wMlEzPTd7IN88US=> MVXTRW5ITVJ?
LAMA-84 M1WwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HtTWlEPTB;MD6xNlk6KM7:TR?= NV;B[HU2W0GQR1XS
Raji MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi0bolKSzVyPUCuNVMyOTdizszN M{\5[XNCVkeHUh?=
LU-65 NWnoNFlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMUOzNFch|ryP M2njTXNCVkeHUh?=
NCI-H187 NWK2bJFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\SZ2lEPTB;MD6xN|kzPCEQvF2= NGPYW|BUSU6JRWK=
GCIY M{ftbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMUS5NFEh|ryP NYDtXYJKW0GQR1XS
NCI-H2107 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq4N4tKSzVyPUCuNVUxQCEQvF2= NUSxUHplW0GQR1XS
NCI-H1522 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f0[2lEPTB;MD6xOVI3PiEQvF2= M4r1fXNCVkeHUh?=
NB6 NH;lSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\NRYtKSzVyPUCuNVU3OjNizszN M1vhcnNCVkeHUh?=
EM-2 NFPrTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEGw[5lKSzVyPUCuNVU4ODZizszN MmrsV2FPT0WU
HCC2218 NITDZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XzZmlEPTB;MD6xOVk5KM7:TR?= MoPlV2FPT0WU
NCI-H748 MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMU[zO|Yh|ryP MYDTRW5ITVJ?
MS-1 NHjjcYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjHVVRoUUN3ME2wMlE3PTN5IN88US=> M2HW[3NCVkeHUh?=
NB5 M3jVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr1bVVWUUN3ME2wMlE3PTl5IN88US=> M1v3e3NCVkeHUh?=
OMC-1 NFPnW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjxTWM2OD1yLkG2Olg5KM7:TR?= NYrmS2s4W0GQR1XS
NCI-H345 NX;BW3NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jOTmlEPTB;MD6xOlkzQCEQvF2= MWHTRW5ITVJ?
L-428 M1rFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLTTWM2OD1yLkG2PVQ2KM7:TR?= NV;URYVMW0GQR1XS
SCH M3nt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMUi2PFUh|ryP MWnTRW5ITVJ?
NCI-H1417 NELmOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMUmyNlch|ryP M1\QNnNCVkeHUh?=
COLO-320-HSR NEnze4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnLcmNvUUN3ME2wMlE6PTN{IN88US=> M3yzcnNCVkeHUh?=
BT-474 M3WyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMkC4PVIh|ryP NFXaPY1USU6JRWK=
GDM-1 NULwSJA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnjXHlKSzVyPUCuNlE6PzFizszN NVPsTGs{W0GQR1XS
NCI-H2196 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLVTWM2OD1yLkKyNlM2KM7:TR?= MWHTRW5ITVJ?
KP-N-RT-BM-1 M1;WR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj1cGxKSzVyPUCuNlI{PDlizszN MnnuV2FPT0WU
KNS-81-FD MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjSTWM2OD1yLkKyPVU5KM7:TR?= MWPTRW5ITVJ?
COLO-668 M1XQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPpTWM2OD1yLkKzOlc2KM7:TR?= NIXxU4NUSU6JRWK=
C2BBe1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17OemlEPTB;MD6yOlc1PyEQvF2= MXjTRW5ITVJ?
Ramos-2G6-4C10 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD1d|BVUUN3ME2wMlI3QTV2IN88US=> MkixV2FPT0WU
CAS-1 NWTMcJp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMkewPVYh|ryP MmTRV2FPT0WU
GOTO Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP2N2xQUUN3ME2wMlI4QDl2IN88US=> M4K5dnNCVkeHUh?=
LP-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvTTWM2OD1yLkK4NFU4KM7:TR?= NI\ZVpNUSU6JRWK=
NCI-SNU-1 NUTrVHNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn5UZFKSzVyPUCuNlk1OjJizszN MV7TRW5ITVJ?
EB-3 Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr2TWM2OD1yLkK5PVc6KM7:TR?= MnzHV2FPT0WU
MHH-NB-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwM{C0NFIh|ryP M2TkcnNCVkeHUh?=
SK-N-FI M1K0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj6TWM2OD1yLkOxOlkzKM7:TR?= MYrTRW5ITVJ?
HCC2157 NELjRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnWTWM2OD1yLkOzPVE{KM7:TR?= M2XhW3NCVkeHUh?=
SIMA MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDoTWM2OD1yLkO0OVgyKM7:TR?= NGLuWodUSU6JRWK=
MDA-MB-134-VI M3L5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD3TWM2OD1yLkO2PVI5KM7:TR?= NE[zW3dUSU6JRWK=
NCI-H1694 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD2TWM2OD1yLkO3JO69VQ>? MXvTRW5ITVJ?
EHEB M1nMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnhU2ZQUUN3ME2wMlM6ODh3IN88US=> NXK0PXh2W0GQR1XS
U-266 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfJNnJKSzVyPUCuN|k5PDZizszN M2rF[nNCVkeHUh?=
LC-1F M3\2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fBcWlEPTB;MD60N|c3PSEQvF2= MljaV2FPT0WU
SHP-77 NGTaPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwNEe4OVUh|ryP NVTIUZlXW0GQR1XS
LS-513 Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwNEmzNFch|ryP MXrTRW5ITVJ?

... Click to View More Cell Line Experimental Data
In vivo The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]
+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[5]
+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+5% Tween 80+ddH2O
For best results, use promptly after mixing. 		2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14
CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03704077 Not yet recruiting Gastric Cancer|Cancer of the Stomach|Stomach Cancer|Gastroesophageal Junction Bristol-Myers Squibb May 15 2019 Phase 2
NCT03199885 Not yet recruiting Breast Adenocarcinoma|HER2/Neu Positive|Recurrent Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7 National Cancer Institute (NCI) May 10 2019 Phase 3
NCT03742986 Not yet recruiting Breast Cancer New York University School of Medicine April 2019 Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic April 1 2019 Phase 1|Phase 2
NCT03725436 Not yet recruiting Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Malignant Solid Neoplasm|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Recurrent Breast Carcinoma|TP53 wt Allele|Unresectable Malignant Solid Neoplasm M.D. Anderson Cancer Center|National Cancer Institute (NCI) March 31 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

selleck catalog

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

  • TAI-1 New

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate New

    Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4 New

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • Docetaxel

    Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Vincristine sulfate

    Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

  • Nocodazole

    Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

  • Cabazitaxel

    Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

    Features:A semi-synthetic derivative of a natural taxoid.

  • Patupilone (EPO906, Epothilone B)

    Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID